Biologics Monitoring: Incongruity between Recommendations and Clinician Monitoring Trends.
Biologics are a commonly used treatment for moderate to severe psoriasis. Monitoring laboratory test overuse provide little definitive benefit to patients. We aim to query a Humana database to gain insight regarding current dermatologist laboratory monitoring practices for psoriasis patients on biologics. Data were obtained from the Humana database. Our cohort included 333 patients with primary ICD-9 diagnosis of psoriasis (696.1) between the years 2008-2013 who are prescribed any biologic medication. Subjects on methotrexate, acitretin or cyclosporine were excluded from the study. We separately queried laboratory tests by CPT codes and quantified based on frequency over a 2-year time period. Percentages of demographic group receiving a laboratory test at a given frequency category were calculated. 46% and 47% of patients received >4 comprehensive metabolic panel and complete blood count tests respectively 2 years after starting a biologic. 18% of individuals age >50 received greater than 4 Basic Metabolic Panel tests respectively 2 years after starting a biologic. Patient comorbidities might confound some of our findings, as these laboratory tests may have been ordered for a comorbidity rather than for biologics side effect monitoring. There are inconsistencies between current monitoring practices and guidelines. Clarifying biologics monitoring recommendations in psoriasis patients may reduce healthcare costs and provider workload.